<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04958330</url>
  </required_header>
  <id_info>
    <org_study_id>SysMU-RARC3</org_study_id>
    <nct_id>NCT04958330</nct_id>
  </id_info>
  <brief_title>Lateral Prostate Capsule Sparing Versus Non Nerve Sparing Robot-assisted Radical Cystectomy-orthotopic Ileal Neobladder for Bladder Cancer in the Male</brief_title>
  <official_title>Lateral Prostate Capsule Sparing Versus Non Nerve Sparing Robot-assisted Radical Cystectomy-orthotopic Ileal Neobladder for Bladder Cancer in the Male</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Seventh Affiliated Hospital of Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the perioperative, functional, and oncologic outcomes between non nerve sparing&#xD;
      and lateral prostate capsule sparing robot-assisted radical cystectomy with orthotopic ileal&#xD;
      neobladder in male patients with bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll male patients with bladder cancer who will undergo robot-assisted&#xD;
      radical cystectomy with orthotopic ileal neobladder. The patients will be distributed into&#xD;
      two comparable groups according to surgical procedures: non nerve sparing group and lateral&#xD;
      prostate capsule sparing group. Patient demographics and pathologic, perioperative,&#xD;
      functional, and oncologic outcomes will be compared between the two groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>day-time and night-time continence rate</measure>
    <time_frame>6 months</time_frame>
    <description>Patients were considered continent when they required 0 or 1 safety pad during the day or at night.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>postoperative sexual function</measure>
    <time_frame>6 months</time_frame>
    <description>The sexual function are evaluated by the international index of erectile function-5 (IIEF-5).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>perioperative complication rate</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operative time</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated blood loss</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence-free survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>lateral prostate capsule sparing group</arm_group_label>
    <description>Patients will be preverved the lateral prostate capsule during the resection of bladder and prostate of the operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non nerve sparing group</arm_group_label>
    <description>Patients will receive standard radical cystectomy (not preserve the neurovascular bundles or lateral prostate capsule) during the operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lateral prostate capsule sparing</intervention_name>
    <description>When resect the bladder and prostate, the lateral prostate capsule will be preserved.</description>
    <arm_group_label>lateral prostate capsule sparing group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Enroll patients who received RARC.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male patients aged 18 or older.&#xD;
&#xD;
          2. Patients those who are diagnosed with urothelial carcinoma.&#xD;
&#xD;
          3. Patients those who are without tumour in the bladder neck or urethra, and prostate&#xD;
             cancer was ruled out by MRI and serum T-PSA&lt;2.5ng/ml.&#xD;
&#xD;
          4. Patients those who are capable of receiving radical cystectomy with orthotopic ileal&#xD;
             neobladder.&#xD;
&#xD;
          5. Patients those who are able to cooperate and complete the follow-up.&#xD;
&#xD;
          6. Patients those who volunteer to participate in this study and sign the informed&#xD;
             consens.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients thsoe who are diagnosed distant metastasis before surgery.&#xD;
&#xD;
          2. Patients those who are diagnosed with other malignancies.&#xD;
&#xD;
          3. Patients those who had received pelvic radiotherapy or major pelvic operation.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen Memorial Hospital,Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kaiwen Li, MD</last_name>
    <phone>+86-15989252628</phone>
    <email>likw6@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian Huang, MD</last_name>
    <phone>+86-20-81332146</phone>
    <email>huangj8@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

